Investigating the Effectiveness of Tresiba� (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus (EU-TREAT)
This trial is conducted in Europe. The aim of this trial is to investigate the effectiveness of Tresiba® (insulin degludec) after switching basal insulin in a population with type 1 or type 2 diabetes mellitus.
EU-TREAT (EUropean TREsiba AudiT)
Study Type: Observational
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
Enrollment: 2302
Study Start Date: December 2015
Study Completion Date: August 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts:
- Tresiba®
Category | Value |
---|---|
Date last updated at source | 2017-07-21 |
Study type(s) | Observational study |
Expected enrolment | 2302 |
Study start date | 2015-12-01 |
Estimated primary completion date | 2016-08-01 |